Jaguar Health (JAGX) announced that the U.S. Food and Drug Administration has approved renewal of Canalevia-CA1. Canalevia-CA1, the company’s conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea in dogs, is available from multiple leading veterinary distributors in the U.S., including Chewy. The renewal for conditional approval is in effect until December 21, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX: